Home Newsfeeds Piper Sandler Maintains Neutral on Lululemon Athletica, Raises Price Target to $320

Piper Sandler Maintains Neutral on Lululemon Athletica, Raises Price Target to $320

Piper Sandler analyst Abbie Zvejnieks maintains Lululemon Athletica (NASDAQ:LULU) with a Neutral and raises the price target from $310 to $320.

byBenzinga Newsdesk

September 2, 2022

1 minute read

Piper Sandler analyst Abbie Zvejnieks maintains Lululemon Athletica (NASDAQ:LULU) with a Neutral and raises the price target from $310 to $320.

AMD, Yum China, Paycom Software And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

By Lisa Levin

November 1, 6:17 AM

U.S. stock futures traded lower this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

AMD

Warren Buffett-Backed BYD Marks Another Milestone With L3 Autonomous Driving Test License For High-Speed Roads

By Benzinga Neuro

December 27, 8:46 AM

This marks the second such license for the company, following its first one obtained in China in July, according to BYD's official Weibo page.

BYDDF

IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying

By Lisa Levin

November 27, 7:26 AM

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

IOBT

Predictive Oncology And Cancer Research Horizons Have Partnered To Drive The Development Of Oncology Drugs Utilizing Predictive Oncology’s PEDAL Platform

By Benzinga Newsdesk

March 17, 7:02 AM

The collaboration will utilize Predictive Oncology's PEDAL technology to evaluate Cancer Research Horizons' pre-clinical drug inhibitors of Glutaminase in order to determine which cancer types and patient

POAI

Piper Sandler Maintains Neutral on Lululemon Athletica, Raises Price Target to $320

Related Posts

AMD, Yum China, Paycom Software And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

Warren Buffett-Backed BYD Marks Another Milestone With L3 Autonomous Driving Test License For High-Speed Roads

IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying

Predictive Oncology And Cancer Research Horizons Have Partnered To Drive The Development Of Oncology Drugs Utilizing Predictive Oncology’s PEDAL Platform